ERBB2 and breast cancer: The GERICO trial demonstrated the feasibility of an adjuvant CT regimen with NPLD + cyclophosphamide in fit elderly women (median age 75 [min–max: 70–82] years) with HR+/HER2-negative BC, with no cardiotoxicity and toxic deaths observed and no deleterious impact on functional independence [35].